InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.93
(
0.09%
)
Bitcoin
62,136.96
(
2.05%
)
Post# of 252439
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: Preciouslife1 post# 112050

Monday, 01/10/2011 12:54:35 PM

Monday, January 10, 2011 12:54:35 PM

Post# of 252439
The first article refers to TB-403 - the anti-PlGF mAb, ThromboGenics and BioInvent partnered with Roche in June 2008. Results from phase I trial were presented in Nov. 2009 and Roche said it will conduct dose-finding study (before starting phase II, I presume), so should start phase II soon:

http://www.genengnews.com/gen-news-highlights/bioinvent-and-thrombogenics-earn-10m-as-roche-progresses-anticancer-agent/81243419/

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up